Peptide formulations targeting metabolic health and fat loss, generically referred to in the wellness industry as KLow or metabolic blends, typically combine growth hormone secretagogues, which indirectly promote fat oxidation through GH signalling, with peptides that have more direct effects on adipose tissue metabolism or appetite regulation. The compounds most commonly included in these formulations include AOD-9604, a fragment of the growth hormone molecule; CJC-1295 with or without DAC; Ipamorelin; and sometimes Tesamorelin or GHRP-6. Understanding what each component does helps evaluate the rationale.
AOD-9604: The Fat Fragment
AOD-9604 is a synthetic analogue of the C-terminus fragment of growth hormone, amino acids 176 to 191 of the growth hormone sequence, which is the portion of the GH molecule responsible for its lipolytic, or fat-breaking, effects without the growth-promoting and glucose-elevating effects of the complete GH molecule. In preclinical studies, AOD-9604 stimulates fat oxidation, reduces adipocyte differentiation, and promotes lipolysis without affecting insulin sensitivity or IGF-1 levels. Human clinical trials for its use as an obesity treatment showed modest effects on body weight without the side effects of full growth hormone. It was studied as a pharmaceutical candidate but was not brought to market as a licensed medicine.
CJC-1295 and Ipamorelin
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone that stimulates the pituitary to release growth hormone. Combined with Ipamorelin, a selective growth hormone secretagogue and ghrelin receptor agonist, it produces pulsatile GH release that mimics the natural nocturnal GH pulse more closely than continuous GH administration. The combination is one of the most commonly used in longevity and body composition peptide protocols. Growth hormone itself promotes lipolysis, particularly visceral fat reduction, lean mass preservation, and recovery from exercise. The CJC-1295/Ipamorelin combination achieves these effects by stimulating endogenous GH release rather than administering exogenous GH.
Metabolic Health Beyond Fat Loss
Growth hormone secretagogues affect metabolic health through multiple pathways beyond direct fat oxidation. GH improves insulin sensitivity in adipose tissue while having complex effects on hepatic and muscle insulin sensitivity. It increases free fatty acid release from adipose tissue, sparing muscle glycogen during exercise. It promotes protein synthesis and lean mass accretion when combined with adequate protein and resistance training. And it has positive effects on sleep quality, specifically promoting slow-wave sleep where GH is naturally secreted most abundantly, creating a beneficial cycle where better GH pulsing improves sleep quality which further improves GH secretion.
Safety Profile and Contraindications
Growth hormone secretagogues are generally considered safer than exogenous growth hormone because they work through physiological pituitary feedback mechanisms that prevent supraphysiological GH levels. However, they are not without contraindications: they should not be used in anyone with active malignancy, as GH promotes cellular proliferation. They may cause water retention and insulin resistance at high doses. They are not appropriate during pregnancy or breastfeeding. People with pre-existing pituitary conditions should use only under medical supervision. The regulatory status varies by jurisdiction, and users should be clear on whether a compound is a licensed medicine, a research compound, or a food supplement in their specific jurisdiction.